KRAS and non-small cell lung carcinoma: Promising results have emerged with KRASG12C inhibitors in NSCLC; in fact, targeting mutant KRAS can reverse the cancer cells’ ability to avoid immune surveillance, and can enhance an immune-attractive microenvironment (182) (Figure 5).